Environmental biotechnology in the postgenomics era

Biotechnology Advances

Volumn 22, Issue 1-2, 2003, Pages 3-8

  Chakrabarty, A M ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Biotechnology; Genome; Postgenomics

Indexed keywords

ENVIRONMENTAL IMPACT; GENETIC ENGINEERING; LAWS AND LEGISLATION; MICROORGANISMS; PATENTS AND INVENTIONS;

LIFE PROCESSES;

BIOTECHNOLOGY;

BIOTECHNOLOGY; ENVIRONMENTAL LEGISLATION; ETHICS; GENOME;

EID: 0242492893     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2003.08.004     Document Type: Conference Paper

References (19)

1. Ambrosone C.B., Freudenheim J.L., Graham S., Marshall J.R., Vena J.E.et al. Cigarette smoking, N-acetyl transferase 2 genetic polymorphisms and breast cancer risk. JAMA. 276:1996;494-1501.
2. Andrews L.B., Fullerton J.G., Holtzman N.A., Motulsky A.G. Assessing genetic risks: implications for health and social policy. 1994;National Academy Press, Washington (DC).
3. Basu T., Gale R.E., Langabeer S., Linch D.C. Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukemia. Lancet. 349:1997;1450.
4. Bell D.A., Taylor J.A., Paulson D.F., Robertson C.N., Mohler J.L., Lucier G.W. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase gene M1 (GSTM1) that increases susceptibility to bladder cancer. J. Nat. Cancer Inst. 85:1993;1159-1164.
5. Beutler E. The molecular biology of G6PD variants and other red cell enzyme defects. Annu. Rev. Med. 43:1992;47-59.
6. Catwright R.A., Glashan R.W., Rogers H.J., Ahmad R.A., Barham-Hall D., Higgins E.et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 2:1982;842-845.
7. Chakrabarty A.M. Diamond v. Chakrabarty: a historical perspective. Chisum D.S., Nard C.A., Schwartz H.F., Newman P., Kieff F.S. Principles of patent law. 1998;783-788 Foundation Press, New York.
8. Chakrabarty A.M. Genetics research and the judicial decisions. Not. Polit. XVIII(65):2002;99-102.
9. Chakrabarty A.M. Patenting life form: yesterday, today, and tomorrow. Kieff F.S. Advances in Genetics, vol. 50:2003;Elsevier, San Diego. [in press].
10. Ilett K.F., David B.M., Detchon P., Castleden W.M., Kwa R. Acetylation phenotype in colorected carcinoma. Cancer Res. 47:1987;1466-1469.
11. Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 56:1996;72-76.
12. 3. Am. J. Ind. Med. 30:1996;16-25.
13. Loeb L. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res. 54:1994;5059-5063.
14. Loechler E.L. The role of adduct site-specific mutagenesis in understanding how carcinogen-DNA adducts cause mutations: perspectives, prospects and problems. Carcinogenesis. 17:1996;895-902.
15. Nebert D.W. Multiple forms of inducible drug-metabolizing enzymes. A reasonable mechanism by which any organism can cope with adversity. Mol. Cell. Biochem. 27:1979;27-46.
16. Newman L.S., Lloyd J., Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ. Health Perspect. 104:1996;937-943.
17. Omenn G.S. Predictive identification of hypersusceptible individuals. J. Occup. Med. 24:1982;369-374.
18. Rothenberg K., Fuller B., Rothstein M., Duster T., Kahn M.J.E., Cunningham R.et al. Genetic information and the workplace: legislative approaches and policy challenges. Science. 275:1997;1755-1757.
19. Taylor J.A., Umbach D.M., Stephens E., Paulson D., Robertson C., Mohler J.L.et al. The role of N-acetylation polymorphisms at NAT1 and NAT2 in smoking-associated bladder cancer. Proc. Natl. Assoc. Cancer Res. 36:1995;282.